胺调节剂在精神分裂症中被破坏-1/糖原合成酶激酶-3β相互作用
Jia-Ren Liu1, Xiao Hui Han2, Koichi Yuki2,3
1Department of Clinical Laboratory, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.
Frontiers in molecular neuroscience
|June 6, 2024
概括
胺可降低精神分裂症中受损-1 (DISC1) 蛋白质和轴突生长,可能导致神经退行. 治疗逆转了这些影响,这表明胺对胺的保护作用.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 精神分裂症中断-1 (DISC1) 是一个关键的支架蛋白质,与精神疾病有关.
- DISC1中的突变与精神分裂症和严重抑郁症有关.
- DISC1调节神经元外生和皮质发育,与糖原合成酶激酶-3β (GSK-3β) 相互作用.
研究的目的:
- 为了研究胺对DISC1和GSK-3β表达的影响.
- 探索GSK-3β活动在DISC1.1中胺诱导的变化中的作用.
- 为了确定,一个GSK-3β对手,可以减轻胺对DISC1和神经元生长的影响.
主要方法:
- 来自小鼠幼的初级神经元细胞培养物用胺和进行了治疗.
- 使用免疫血块测量了DISC1,GSK-3β和分裂-caspase-3的水平.
- DISC1-GSK-3β结合通过共免疫沉进行评估.
- 通过测量轴突和树长度来量化神经外生长.
主要成果:
- 氨酸以剂量和时间依赖的方式降低了DISC1水平和GSK-3β酸化,表明GSK-3β活性增加.
- 显著减弱了胺减少DISC1水平的作用.
- 胺减少了DISC1-GSK-3β共同免疫沉降和轴突长度,可以逆转这些影响.
结论:
- 急性胺剂的使用降低了DISC1水平和轴突生长.
- 可以抵消 ketamine 引起的 DISC1 的下降,并促进轴突生长.
- 这项研究确立了DISC1调节与胺诱导的神经退行性影响之间的联系.
更多相关视频
09:07Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
Published on: August 15, 2017
12.0K
04:44Author Spotlight: Studying Drug Impacts on Brain Signals Using Dual LFP Recording Protocol in Mice
Published on: February 16, 2024
1.5K
相关概念视频
01:27Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...